Drugs by condition
Drugs approved for rosacea
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
17
Still marketed, NDA or BLA
Drug classes
6
Novel drugs
2
New molecular entities and new biologics
In development
0
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for rosacea.
All approved drugs for rosacea, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 50 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Nitroimidazole Antimicrobial (4)
- Metrogel Metronidazole · Galderma Labs Lp · 2005
- Metrolotion Metronidazole · Galderma Labs Lp · 1998
- Noritate Metronidazole · Bausch · 1997
- Metrocream Metronidazole · Galderma Labs Lp · 1995
Antiparasitic (1)
- Soolantra Ivermectin · Galderma Labs Lp · 2014
Tetracycline-class Drug (1)
- Oracea Doxycycline · Galderma Labs Lp · 2006
Aminoglycoside Antibacterial (1)
- Zylet Loteprednol Etabonate, Tobramycin · Bausch and Lomb · 2004
Corticosteroid (1)
- Maxidex Dexamethasone · Harrow Eye · 1962
Class not listed in FDA's data (9)
- Rhofade Oxymetazoline Hydrochloride · Mayne Pharma · 2017
- Lotemax Loteprednol Etabonate · Bausch and Lomb · 1998
- Emrosi Minocycline Hydrochloride · Journey · 2024
- Epsolay Benzoyl Peroxide · Mayne Pharma · 2022
- Zilxi Minocycline Hydrochloride · Journey · 2020
- Finacea Azelaic Acid · Leo Pharma As · 2015
- Mirvaso Brimonidine Tartrate · Galderma Labs Lp · 2013
- Finacea Azelaic Acid · Leo Pharma As · 2002
- Omnipred Prednisolone Acetate · Sandoz · 1973
Drugs in development for rosacea
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials list this condition.
More on rosacea: recruiting trials · published research
Related in dermatology: Acne
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.